Innovation Pharmaceuticals (IPIX) Stock Price, News & Analysis

Company Overview

Innovation Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceutical products for diseases with significant unmet medical needs. The company’s research has centered on therapies designed to address cancer, inflammatory conditions, infectious diseases and gastrointestinal disorders.

Its development portfolio has historically included Brilacidin, a defensin-mimetic drug candidate investigated for inflammatory bowel disease, oral mucositis and infectious diseases, as well as Kevetrin, an investigational cancer therapy intended to reactivate the tumor-suppressor protein p53. The company has also developed Prurisol, a candidate studied for psoriasis.

Innovation Pharmaceuticals was formerly known as Cellceutix Corporation and has operated as a development-stage company rather than a commercial pharmaceutical manufacturer. Company materials have historically identified Leo Ehrlich as chief executive officer. The company’s programs have primarily been advanced through research collaborations and clinical development activities, and no assurance is provided that its investigational candidates will receive regulatory approval or become commercially available.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.05
• Volume: 1,000 shs
• Average Volume: 188,708 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:IPIX
• CIK: 1355250
• Web: ipharminc.com
• Phone: (978) 921-4125
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A